Shingles in a composite court reporter, now retired, is read three ways in the NU559 Unit 9 review: waning T-cell control, viral replication and nerve inflammation, each with its drugs. Searches like "nu 559 unit 9 assignment example", "nu559 unit 9 sample" and "nu559 unit 9 example" land here.
What the Immune System Allowed, What the Virus Is Doing, What the Nerve Is Suffering: Shingles at 67
[Student Name]
Purdue University Global
NU559: Essentials of Advanced Pathophysiology and Pharmacology
Unit 9 Infection and Inflammation Review
[Instructor Name]
[Date]
The patient is a composite; agents and values in brackets are illustrative.
Presentation
Ms. [T.], 67, spent thirty years as a court reporter. Three days ago she felt burning and tingling in a band around the left side of her chest, and she thought she had strained a muscle. Yesterday, red patches appeared in the same band and turned into clusters of small blisters on a red base, stopping sharply at the midline of her back and chest. The rash follows the T5 dermatome. She had chickenpox as a child. She has not had a shingles vaccine.
1. Reactivation: What Her Immune System Allowed
Varicella zoster virus causes chickenpox in childhood. During that illness, the virus travels up sensory nerves from the skin and establishes latency in the dorsal root ganglia, the clusters of sensory nerve cell bodies beside the spinal cord (Cohen, 2013). It stays there for life, its genome present but largely silent.
What keeps it silent is cell-mediated immunity. Varicella-specific T cells survey the ganglia and suppress reactivation. With age, the number and function of those T cells decline, a part of immune aging. Reactivation becomes more likely after about age 50, and more likely again in people whose immunity is suppressed by disease or drugs. Shingles is not a new infection but a latent one that her declining T-cell surveillance could no longer contain. Why reactivation happened in this ganglion, at this time, is not known.
2. Active Infection: What the Virus Is Doing
Once reactivated, the virus replicates in the ganglion and travels down the sensory nerve to the skin that nerve supplies. That is why the rash is confined to one dermatome and stops at the midline: each dorsal root ganglion serves one side of one band of skin. The burning she felt before the rash appeared was the virus inflaming the nerve on its way to the skin.
Drug. [Valacyclovir], taken by mouth, is converted in the liver and intestine to [acyclovir], giving higher blood levels than oral acyclovir itself. Acyclovir's selectivity comes from its activation. It is a nucleoside analog that must be phosphorylated three times to act. The first phosphorylation requires thymidine kinase encoded by the virus, an enzyme that uninfected cells lack, so the drug is activated mainly inside infected cells. Host enzymes then add two more phosphates. The triphosphate form competes with the natural nucleotide at the viral DNA polymerase and, once incorporated into the viral DNA, stops the chain from growing, because it lacks the chemical group needed to add the next nucleotide.
Timing follows from the mechanism. Antivirals interrupt replication, and replication is front-loaded in the first days of the rash. Starting treatment within 72 hours of rash onset shortens the duration of new lesions and speeds healing, and it may reduce acute pain (Cohen, 2013). Ms. [T.]'s rash appeared yesterday, well within that window, so she should start today. After the first few days, when replication has largely ended, there is less for the drug to act on.
3. The Nerve: What It Is Suffering
The virus damages the nerve as well as the skin. Replication and the immune response to it inflame the ganglion and the nerve, and some neurons die. Pain in the acute phase comes from that inflammation.
In some people, pain persists after the rash heals. Postherpetic neuralgia is pain lasting three months or more after the rash, and its risk rises with age, with severe acute pain and with a large rash (Johnson & Rice, 2014). The mechanism is nerve injury. Damaged sensory neurons fire spontaneously, sensitize neurons in the spinal cord and lose their normal inhibition, and the skin can become painful to light touch, a feature called allodynia.
Drugs. Treatments for postherpetic neuralgia act on that nerve injury, not on the virus.
1. Gabapentinoids, [gabapentin] and [pregabalin], attach to an accessory protein of the calcium channels in sensory nerve terminals, reducing the release of excitatory neurotransmitters. They carry dizziness and sedation, which matter at 67.
2. Topical [lidocaine] blocks sodium channels in the damaged nerve endings in the skin, with little systemic effect.
3. Topical [capsaicin] depletes and damages the pain fibers in the skin.
4. Tricyclic antidepressants, such as [nortriptyline], enhance descending inhibition by blocking reuptake of norepinephrine and serotonin, but their anticholinergic effects limit use in older adults.
Corticosteroids. Adding a corticosteroid to an antiviral in the acute phase may modestly reduce acute pain, but a systematic review found no clear evidence that it prevents postherpetic neuralgia (Han et al., 2013). It is a dampening option for acute inflammation, not a prevention for nerve damage, and it carries its own risks in older adults.
What She Is Told Today
Ms. [T.] is told that the blisters are contagious to anyone who has never had chickenpox or the chickenpox vaccine, so she keeps the rash covered and avoids contact with pregnant women without immunity, newborns and people with weakened immune systems until the blisters have crusted. She takes the antiviral for the full course even if the rash improves. She is asked to call at once if the rash spreads beyond the band, if she develops a fever and feels unwell, or if any blisters appear on the tip of her nose or near an eye, since involvement of the ophthalmic nerve can threaten sight. And she is told that the burning may outlast the rash, that treatment exists if it does, and that she should report it early rather than wait months.
4. Immunity Again: What a Vaccine Can Support
The illness started with a decline in T-cell immunity, and prevention returns to that point. The recombinant zoster vaccine combines a varicella glycoprotein, glycoprotein E, with an adjuvant that strongly stimulates the immune response, boosting the varicella-specific T-cell immunity whose decline allows reactivation. In adults aged 50 and older, it reduced the risk of shingles by about 97 percent (Lal et al., 2015).
Ms. [T.] should be offered the vaccine once her current episode has resolved, because a first episode does not protect against another.
Placing the Drugs in Time
1. Before the illness: recombinant zoster vaccine, acting on T-cell immunity.
2. First 72 hours of rash: [valacyclovir], acting on viral replication.
3. Acute phase: analgesia, and possibly a short corticosteroid course, acting on nerve inflammation.
4. After the rash: gabapentinoids and topical agents, acting on nerve injury, if pain persists.
References
Cohen, J. I. (2013). Herpes zoster. New England Journal of Medicine, 369(3), 255-263. https://doi.org/10.1056/NEJMcp1302674
Han, Y., Zhang, J., Chen, N., He, L., Zhou, M., & Zhu, C. (2013). Corticosteroids for preventing postherpetic neuralgia. Cochrane Database of Systematic Reviews, 2013(3), Article CD005582. https://doi.org/10.1002/14651858.CD005582.pub4
Johnson, R. W., & Rice, A. S. C. (2014). Postherpetic neuralgia. New England Journal of Medicine, 371(16), 1526-1533. https://doi.org/10.1056/NEJMcp1403062
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà , J., Vesikari, T., Watanabe, D., Weckx, L., Zahaf, T., & Heineman, T. C. (2015). Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine, 372(22), 2087-2096. https://doi.org/10.1056/NEJMoa1501184
How this NU559 Unit 9 example is structured
The review is ordered by the course of the disease rather than by drug class, so each agent appears at the moment in the illness where its target exists. That choice explains timing. Antivirals help most when started within 72 hours of rash onset because replication is what they interrupt, and replication is front-loaded; the review makes that point from mechanism before citing the evidence. Selectivity is explained through viral thymidine kinase, which phosphorylates the drug only inside infected cells, and through chain termination at the viral DNA polymerase. Corticosteroids are discussed as a dampening option with modest benefit for acute pain and no clear effect on later neuralgia, sourced to a systematic review. The vaccine section explains how an adjuvanted glycoprotein vaccine boosts the cellular immunity whose decline started the episode, closing the loop the first heading opened.
Get an NU559 Unit 9 example written to your instructions
Some Unit 9 prompts build the review around an infection, others around a chronic inflammatory disease such as rheumatoid arthritis. Share the condition your NU559 section named, the case if there is one and the rubric. A sample review tying each immune process to its drugs arrives in 24-48h, and there is no cost for a first request. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
NU559 Unit 9 questions, answered
Should the review cover antibiotics if the condition is viral?
Only to explain why they have no role, or to address a secondary bacterial infection of the skin if the case raises one. A sentence contrasting antiviral and antibacterial targets can strengthen the mechanism argument. Beyond that, antibiotic material in a viral review reads as padding and takes space the immune discussion needs more.
How much immunology is enough for this unit?
Enough to name the arm of immunity involved and explain what its decline or activity does in this condition. For zoster that means cell-mediated immunity, not antibodies, since antibody levels stay measurable while T-cell control fades. A detailed account of every cytokine is rarely rewarded unless the prompt asks for it, and it tends to crowd out the drug links.
Is a review different from a case study in this course?
Usually. A review organizes knowledge about a condition and its treatments, often with a composite patient as illustration, while a case study reasons through one patient's findings to a plan. Prompts vary, so look at the verbs yours uses; summarize and synthesize point toward a review, while analyze and recommend point toward a case.